NRSN

Business Context and Reporting Period

Company: NeuroSense Therapeutics Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: December 2, 2024
Context: The Company announced a private placement offering to raise capital for clinical development and working capital.

Key Financial Metrics

Capital Raised: Approximately $5.0 million in gross proceeds (before expenses).
Instrument Details:

• Ordinary Shares: 2,343,729 shares at $1.25 per share.
• Pre-Funded Warrants: 1,656,271 warrants at $1.2499 per warrant (exercise price $0.0001).
• Ordinary Warrants: 8,000,000 warrants (exercise price $1.25, 5-year term).

Payment Schedule:

• First tranche: $2.8 million due by December 5, 2024.
• Remaining proceeds: Due by December 18, 2024, or at the investor's option, by March 31, 2025.

Other Metrics: The filing text does not provide specific values for revenue, profit, cash flow, margins, or existing debt levels.

Material Changes

This filing reports a material change in the Company's capital structure through the issuance of new equity and warrants. The transaction involves a single investor and the Company's CEO, Alon Ben-Noon. The offering price represents a premium to the market price at the time of the announcement.

Guidance, Outlook, and Risks

Use of Proceeds: Net proceeds will be used for:

• Clinical development of the lead product candidate, PrimeC, for ALS.
• Preclinical and clinical R&D for potential investigational new drug applications for Alzheimer's and Parkinson's disease.
• Future R&D of new product candidates.
• Working capital and general corporate purposes.

Management Commentary: The Company intends to file a Form F-3 registration statement for resale of the securities within three business days of payment. Risks and Contingencies:

• Listing Risk: Risk of failing to satisfy Nasdaq listing conditions.
• Clinical Trial Risk: Potential delays in reporting top-line results from the PARADIGM Phase 2b ALS clinical trial.
• Capital Risk: Insufficient capital to complete PrimeC development or unexpected R&D costs.
• Regulatory Risk: Uncertainty regarding outcomes of meetings with the FDA and Health Canada.

Unusual Items: The CEO participated as a purchaser in this private placement.

Investor Verification Checklist

• Confirm the final closing date and total amount of proceeds actually received versus the expected $5.0 million.
• Verify the Company's current cash runway and whether the $5.0 million is sufficient to reach the next major clinical milestone for PrimeC.
• Monitor the status of the Form F-3 registration statement for resale of the securities.
• Review the latest updates on the PARADIGM Phase 2b ALS clinical trial timeline and any potential delays.
• Check the Company's compliance status with Nasdaq listing requirements.